{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:32Z","timestamp":1789684892094,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.leukres.2017.01.005","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T13:00:27Z","timestamp":1484139627000},"page":"65-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Current approach to the treatment of chronic myeloid leukaemia"],"prefix":"10.1016","volume":"55","author":[{"given":"Ivan","family":"Pasic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2017.01.005_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2017.01.005_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2017.01.005_bib0020","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/376785a0","article-title":"Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents","volume":"376","author":"Kharbanda","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2017.01.005_bib0025","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2017.01.005_bib0035","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/1097-0142(19821101)50:9<1683::AID-CNCR2820500904>3.0.CO;2-X","article-title":"Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia","volume":"50","author":"Bolin","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.01.005_bib0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.leukres.2017.01.005_bib0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","article-title":"Interferons alpha and beta as immune regulators\u2013a new look","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2017.01.005_bib0050","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2017.01.005_bib0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.curtheres.2011.06.002","article-title":"Interferon alfa versus interferon alfa plus cytarabine combination therapy for chronic myeloid leukemia: a meta-analysis of randomized controlled trials","volume":"72","author":"Chen","year":"2011","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.leukres.2017.01.005_bib0060","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0065","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0070","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0075","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","article-title":"Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.01.005_bib0080","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-Year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0090","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0095","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1002\/ajh.23804","article-title":"First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis","volume":"89","author":"Vigan\u00f2","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0100","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.005_bib0105","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0110","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European leukemia net study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325 an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0125","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2017.01.005_bib0135","first-page":"315","article-title":"Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"4","author":"Mughal","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.leukres.2017.01.005_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2017.01.005_bib0145","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5581\/1516-8484.20110124","article-title":"Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia","volume":"33","author":"Bitencourt","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.leukres.2017.01.005_bib0150","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.005_bib0155","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0160","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0165","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0170","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0175","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0180","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0185","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2017.01.005_bib0190","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107) a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0195","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107) a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or \u2013intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0200","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0205","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0210","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0215","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0220","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"Mealing","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0230","first-page":"375","article-title":"SKI-606 a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.005_bib0235","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606 a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.005_bib0240","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0245","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534 a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2017.01.005_bib0260","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0265","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.005_bib0270","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0275","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.01.005_bib0280","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/asheducation-2008.1.427","article-title":"Novel agents in CML therapy: tyrosine kinase inhibitors and beyond","volume":"2008","author":"Melo","year":"2008","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"10.1016\/j.leukres.2017.01.005_bib0285","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":"Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells","volume":"25","author":"Allan","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0290","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404772","article-title":"BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge","volume":"21","author":"Legros","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.01.005_bib0300","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib","volume":"13","author":"Cortes","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2017.01.005_bib0305","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/cncr.29240","article-title":"Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-up","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.01.005_bib0310","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0315","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0320","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V126.23.345.345","article-title":"Long-term follow-up of the french 1 stop imatinib study (STIM1) in chronic myeloid leukemia patients","volume":"126","author":"Etienne","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0325","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0330","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0335","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0340","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.01.005_bib0345","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or \u2013intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0350","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140mg once daily versus 70mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0355","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or \u2013intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0360","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or \u2013intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0365","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"le Coutre","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0370","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0375","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0380","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or \u2212intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.005_bib0385","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","article-title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors","volume":"90","author":"Gambacorti-Passerini","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0390","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/sj.onc.1205452","article-title":"BCR\/ABL P190 transgenic mice develop leukemia in the absence of Crkl","volume":"21","author":"Hemmeryckx","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2017.01.005_bib0395","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0400","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0405","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.480.480","article-title":"The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with the T 315I Mutation","author":"Nicolini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0410","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.01.005_bib0415","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2017.01.005_bib0420","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0425","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2017.01.005_bib0430","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0435","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0440","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.005_bib0445","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bmt.2008.218","article-title":"Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase","volume":"42","author":"Bittencourt","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2017.01.005_bib0450","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1592\/phco.25.3.325.61593","article-title":"Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach","volume":"25","author":"Skrepnek","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.leukres.2017.01.005_bib0455","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2013.05.012","article-title":"A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2017.01.005_bib0460","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","article-title":"Is there a best TKI for chronic phase CML","volume":"126","author":"Larson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.005_bib0465","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Experts","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T18:07:04Z","timestamp":1601316424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261730005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":93,"alternative-id":["S014521261730005X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current approach to the treatment of chronic myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}